Survival data. After median follow-up of 64 months for surviving patients, 190 (64%) were alive and 105 (36%) had died. (A) Median OS was not reached. Estimated 3-year OS was 73% (95% CI, 68%-78%). (B) Median EFS was 78.1 months (95% CI, 41.8 months to not reached), more than double the historical control of 30 months (95% CI, 22-38 months); 3-year EFS was 59% (95% CI, 54%-66%). (C) Median DFS was 81.7 months (95% CI, 58.4 months to not reached); 3-year DFS was 66% (95% CI, 60%-72%). (D) In comparison with patients with BMI <30 kg/m², those with BMI between 30 and 40 kg/m² and those with BMI >40 kg/m² had significantly higher risk of death (HR, 1.72 and 3.29, respectively). Estimated 3-year survival for patients with BMI <30 kg/m² was 79% (95% CI, 73%-85%); for those with BMI from 30 to 40 kg/m², 3-year survival was 64% (95% CI, 54%-77%); and for those with BMI >40 kg/m², 3-year survival was 46% (95% CI, 29%-72%; P = .0003). (E) Ph-like signature was associated with worse survival; 3-year OS rate was 63% (95% CI, 50%-81%) for patients with Ph-like signature, in contrast to 81% (95% CI, 73%-89%) for those without Ph-like signature. (F) Detection of MRD using quantitative polymerase chain reaction after induction therapy was strongly associated with worse DFS; 3-year DFS rate for those with undetectable MRD was 85% (95% CI, 74%-98%); in contrast, for those with detectable MRD, DFS was only 54% (95% CI, 41%-71%; P = .001). KM est, Kaplan-Meier estimate.